Changes in Beneficial Ownership · 4
ADARx Pharmaceuticals, Inc.
ADRXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-09282026_040901.xml
Filing details
- Report period
- 2026-09-24
- Issuer
- ADARx Pharmaceuticals, Inc.
- Issuer CIK
- 0001802369
- Trading symbol
- ADRX
Reporting owner 1
- Name
- Li Zhen
- Reporting owner CIK
- 0001729510
- Relationship
- Director · Officer · 10% owner
- Officer title
- President and CEO
- Address
- C/O ADARX PHARMACEUTICALS, INC., 5871 OBERLIN DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | 17 | 2026-09-24 | A · Form 4 | 1,024,152 | A | 0 | [F1] | 2036-09-23 | Common Stock | 1,024,152 | 1,024,152 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.↩ 1
Signature 1
- Signed
- /s/ Jiang Bian, Attorney-in-Fact
- Date
- 2026-09-28
Company context
We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company.